Xenitra Limited has secured $1.25 million through a share placement to accelerate its OTC medicines rollout and expand its OPAL RWA token ecosystem, with shareholder approval pending for attached options.
- Placement raises $1.25 million at $0.003 per share
- Up to 416 million shares issued with attaching options
- Funds earmarked for OTC medicines and token ecosystem growth
- Novus Capital leads placement, earning fees and options
- Shareholder approval required for option issuance
Capital Raise Targets Growth and Innovation
Xenitra Limited (ASX:XEN) has successfully secured $1.25 million from institutional and sophisticated investors via a placement priced at $0.003 per share. The capital injection aims to fuel the next phase of growth, focusing on accelerating its over-the-counter (OTC) medicines expansion and scaling the OPAL RWA token ecosystem across new brands. Alongside the shares, the placement includes unquoted options exercisable at $0.004 each, expiring in April 2028, subject to shareholder approval.
Strategic Allocation of Funds
The fresh capital will support multiple strategic priorities: fast-tracking the rollout of OTC medicines, which recently gained momentum following Xenitra's acquisition of Hong Kong Fukang Trading Co. and operationalisation of its pharmaceutical licenses; broadening the OPAL token ecosystem that underpins its blockchain-based digital commerce platform; and bolstering working capital and infrastructure to sustain growth initiatives. This follows the company's recent commercial traction with the OPAL token, which recorded over $100,000 in sales within the first week of its EZZ Life Sciences launch, highlighting the ecosystem's potential to drive high-margin sales and engagement.
Placement Mechanics and Lead Manager Role
The placement will issue up to 416,666,667 fully paid ordinary shares under the company's existing Listing Rule 7.1 capacity. For every two shares issued, investors receive one attaching option, a structure designed to incentivise longer-term shareholder participation. Novus Capital Limited acted as the sole lead manager, earning a 6% management and selling fee on the placement amount. Additionally, Novus is set to receive 15 million shares and 30 million options, also contingent on shareholder approval.
Dilution and Shareholder Approval Considerations
The issuance of such a large number of shares and options will increase Xenitra’s capital base significantly, with potential dilution effects for existing shareholders. The options’ exercise price of $0.004 is marginally above the placement price, suggesting a modest premium for future capital raising. Shareholder approval will be a crucial milestone, as it will determine the final structure of the capital raise and the extent of dilution. Investors should watch for upcoming shareholder meetings to gauge support for the options issuance.
Positioning Amid Rapid Sales Growth and Market Expansion
This capital raise comes on the back of a surge in sales, with Xenitra posting a 300% jump in Q3 revenue to $8.3 million, driven by its Nutritionals division and the $30 million Danone partnership. The company’s recent acquisition of a Hong Kong OTC pharmacy has fortified its presence in the Asian pharmaceutical market, complementing the rollout of its blockchain-based OPAL token ecosystem designed to enhance product authentication and customer loyalty. These initiatives collectively position Xenitra to capitalise on growing demand for health and wellness products in Asia, supported by innovative digital commerce models.
The placement’s timing and scale underscore Xenitra’s ambition to consolidate its foothold in both traditional OTC markets and emerging blockchain-enabled sales channels, leveraging the momentum from its $100,000 sales milestone and 300% sales surge in Q3. However, the ultimate impact of this capital raise will depend on execution, market reception, and shareholder endorsement of the option component.
Bottom Line?
Xenitra’s $1.25 million placement aims to accelerate its dual growth engines of OTC medicines and tokenised commerce, but shareholder approval and effective deployment will be key to unlocking value.
Questions in the middle?
- Will shareholders approve the attaching options and what impact will that have on dilution?
- How quickly can Xenitra scale the OPAL token ecosystem across additional brands and markets?
- Can the OTC medicines expansion maintain momentum amid competitive pressures in Asia?